Kathrin Kahnert, Stefan Andreas, Christina Kellerer, Johanna I Lutter, Tanja Lucke, Önder Yildirim, Mareike Lehmann, Jochen Seissler, Jürgen Behr, Marion Frankenberger, Robert Bals, Henrik Watz, Tobias Welte, Franziska C Trudzinski, Claus F Vogelmeier, Peter Alter, Rudolf A Jörres
We studied whether in patients with COPD the use of metformin for diabetes treatment was linked to a pattern of lung function decline consistent with the hypothesis of anti-aging effects of metformin. Patients of GOLD grades 1-4 of the COSYCONET cohort with follow-up data of up to 4.5 y were included. The annual decline in lung function (FEV1 , FVC) and CO diffusing capacity (KCO, TLCO) in %predicted at baseline was evaluated for associations with age, sex, BMI, pack-years, smoking status, baseline lung function, exacerbation risk, respiratory symptoms, cardiac disease, as well as metformin-containing therapy compared to patients without diabetes and metformin...
January 26, 2022: Scientific Reports